genai / news / / Moneycontrol
OpenAI is rolling out an early version of an artificial intelligence model meant to speed up drug discoveries.
OpenAI has launched GPT-Rosalind, an AI model specifically for life sciences research.
KEY POINTS
- GPT-Rosalind will be initially available to select business customers like Amgen, Moderna, and the Allen Institute.
- Shares of existing drug discovery companies fell sharply following OpenAI's model announcement.
- OpenAI's GPT-Rosalind includes high-precision security flags to detect potential bioweapon-related use.
COMPANIES
Summarized by Newsio from Moneycontrol. How we summarize →